Key result
Moxonidine matches ramipril for lowering BP in overweight dysglycemic patients while also reducing heart rate.
Why the study?
Moxonidine improves insulin sensitivity and RAAS-blockers are recommended first-line in diabetes, but their comparative effects on blood pressure and glucose metabolism in overweight patients with hypertension and dysglycemia warranted evaluation.
Does moxonidine improve blood pressure and glucose metabolism compared to ramipril in overweight patients with mild-to-moderate hypertension and impaired fasting glucose or type 2 diabetes?
RCT
Double-blind
randomized
Does moxonidine improve blood pressure and glucose metabolism compared to ramipril in overweight patients with mild-to-moderate hypertension and impaired fasting glucose or type 2 diabetes?
Moxonidine 0.4 mg and ramipril 5 mg are equally effective for blood pressure lowering and metabolically neutral in overweight patients with mild-to-moderate hypertension and dysglycemia.
No takes yet. Share an insight, caveat, or question.
Supports moxonidine as an alternative to ramipril in overweight patients with hypertension and dysglycemia; extends options for centrally acting agents with heart rate benefit.
Valensi et al. (2024) conducted an RCT in Overweight patients with mild-to-moderate hypertension and impaired fasting glucose or type 2 diabetes. Moxonidine vs. Ramipril 5 mg once-daily was evaluated on SiDBP and SiSBP. Moxonidine 0.4 mg and ramipril 5 mg were equally effective in lowering blood pressure in overweight patients with hypertension and dysglycemia, with moxonidine also reducing heart rate (p=0.017).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: